Triple-Negative Breast Cancer

Elizabeth Mittendorf, MD, PhD, reviews the case of a 53-year-old woman with PD-L1+ TNBC breast cancer and the panel discusses relevant clinical trial data.

Experts in breast cancer discuss efficacy data from the IMpassion130 clinical trial.

The panel of experts review the study design and key efficacy data of the KEYNOTE-355 trial.

The panel discusses treatment options and considerations for a 53-year-old woman with PD-L1+ triple-negative breast cancer.

Elizabeth Mittendorf, MD, PhD, presents the case of a 34-year-old woman with PD-L1–positive triple-negative breast cancer.

Experts in the management of breast cancer review some treatment considerations surrounding the use of PARP inhibitors in BRCA1/2–positive triple-negative breast cancer.

Experts in the management of breast cancer review clinical trial data using PARP inhibitors in the treatment of BRCA1/2-mutated TNBC.

Elizabeth Mittendorf, MD, PhD, and Ruta Rao, MD, present the case of a 48-year-old woman with stage T2N1 TNBC.

Pathologist David G. Hicks, MD, discusses the impact of residual disease in breast cancer treatment outcomes.

The panel of experts share their treatment recommendations for patients with residual disease after an incomplete response to TNBC therapy.

Ruta Rao, MD, discusses practical considerations regarding the use of sacituzumab govitecan in patients with relapsed/refractory TNBC.

Experts in the field of breast cancer review the role of genetic testing in the selection of treatment for patients with TNBC.

The panel of experts in breast cancer discuss enrollment of patients with TNBC in clinical trials, including considerations and barriers.

Hope Rugo, MD, discusses the case of a 49-year-old woman diagnosed with metastatic triple-negative breast cancer.

Dr Rugo educates on early stage treatment options and molecular testing guidelines for patients with metastatic triple-negative breast cancer.

An expert in breast oncology discusses the IMpassion130 and KEYNOTE-355 clinical trials.

Hope Rugo, MD, continues to discuss key clinical trials affecting metastatic triple-negative breast cancer, including IMpassion131.

Dr Hope Rugo discusses the importance of testing for germline BRCA1/2 mutations in patients with triple-negative breast cancer.

An expert explains the different types of immune-related adverse effects associated with the use of immune checkpoint inhibitors.

Hope Rugo, MD, provides insights on best practices for managing metastatic TNBC in community settings.